
MarketAxess Announces Trading Volume Statistics for April 2025
NEW YORK--(BUSINESS WIRE)--MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced trading volume and preliminary variable transaction fees per million ('FPM') for April 2025. 1
Trading Records for April 2025
Select April 2025 Highlights* (See tables 1-1C and table 2)
The MarketAxess platform performed very well during increased volatility in April, providing our clients with deep liquidity through Open Trading.
Market ADV increased significantly year-over-year across most product areas with record levels in U.S. high-yield, municipals and U.S. government bonds driven by an increase in volatility.
Record Open Trading ADV of $5.7 billion with estimated share of total credit 2 of 38%, up from 34% in the prior year, and up from 37% in March 2025, reflecting the increasing importance of our differentiated liquidity to clients in more volatile periods.
We delivered strong progress with our new initiatives across the client-initiated, portfolio trading and dealer-initiated channels that also contributed to the strong performance in April.
90% of all portfolio trading ADV was executed over X-Pro in April.
April was the second highest monthly ADV in U.S. high-grade behind March 2025.
U.S. high-yield ADV of $2.0 billion represented the highest monthly ADV level since February 2023, driven in part by a strong increase in ETF market maker activity. ETF market maker trading volume was the highest level since November 2023.
Continued strength in emerging markets ADV, which was a record $4.3 billion, was driven by a 30% increase in hard currency ADV to a record $2.6 billion, and a 23% increase in local markets ADV. As volatility picked up, investors relied on multiple MarketAxess protocols to navigate market uncertainty, including Open Trading, portfolio trading and request-for-market, or RFM.
Block trading in emerging markets benefitted from the launch of our targeted block solution in late 2024, which has generated cumulative trading volume of over $1.4 billion since launch.
Record eurobonds ADV benefited from record eurobond portfolio trading, which was driven by our increased sales efforts.
Block trading in eurobonds benefitted from the launch of our targeted block solution in January 2025, which has generated cumulative trading volume of over $2.6 billion since launch.
Record municipal bond ADV was driven by increased market volatility and strong increases in taxable and record tax-exempt trading volumes.
The lower estimated market share in municipals was in part driven by a shift to larger sized notional trades in the market.
Our rates business reported an all-time single-day record of $102.3 billion U.S. government bonds notional traded on April 9 and delivered record ADV of $39.1 billion with estimated market share of 2.8% in April.
April 2025 Variable Transaction Fees Per Million 1 (See table 1D)
The decline in total credit FPM compared to the prior year was driven principally by protocol mix. The increase month-over-month was principally driven by product mix.
The decrease in total rates FPM compared to the prior year and the prior quarter was driven by the impact of product mix.
*All comparisons versus April 2024 unless noted.
Table 1A: Market ADV
Month % Change
Apr-25 Mar-25 Apr-24 YoY MoM
MARKET ADV ($ millions)
Credit
U.S. High-Grade TRACE
$
44,647
$
45,024
$
36,735
22
%
(1
)%
U.S. High-Yield TRACE
14,565
13,605
10,253
42
7
Total U.S. Credit TRACE
59,212
58,629
46,988
26
1
Municipal Bonds MSRB
15,427
9,895
6,961
122
56
Rates
U.S. Government Bonds TRACE
$
1,354,981
$
1,097,090
$
867,900
56
%
24
%
Agency TRACE
4,064
3,957
4,097
(1
)
3
U.S. Trading Days 4
21
21
22
U.K. Trading Days 4
20
21
21
Expand
Table 1B: Estimated Market Share 5
Month % Change
Apr-25 Mar-25 Apr-24 YoY MoM
MKTX ESTIMATED MARKET SHARE (%)
U.S. High-Grade
% of U.S. High-Grade TRACE (incl. SD PT) 5
19.4
%
20.0
%
18.2
%
1.2
%
(0.6
)%
% of U.S. High-Grade TRACE (excl. SD PT) 5
19.3
%
19.2
%
17.9
%
1.4
0.1
U.S. High-Yield
% of U.S. High-Yield TRACE (incl. SD PT) 5
14.1
%
12.8
%
14.2
%
(0.1
)%
1.3
%
% of U.S. High-Yield TRACE (excl. SD PT) 5
13.5
%
12.5
%
13.9
%
(0.4
)
1.0
Other Credit Products
% of Municipal Bonds MSRB
4.8
%
6.4
%
6.4
%
(1.6
)%
(1.6
)%
Rates
% of U.S. Government Bonds TRACE
2.8
%
2.5
%
2.3
%
0.5
%
0.3
%
Expand
Table 1C: Strategic Priorities ADV 6
Month % Change
Apr-25 Mar-25 Apr-24 YoY MoM
STRATEGIC PRIORITIES ADV ($ millions)
Client-Initiated Channel
U.S. Credit Block Trading
$
3,751
$
3,450
$
2,489
51
%
9
%
Emerging Markets Block Trading
1,579
1,717
1,232
28
(8
)
Eurobonds Block Trading
497
510
265
88
(3
)
Portfolio Trading Channel
Total MKTX Portfolio Trading 6
$
1,790
$
1,525
$
901
99
%
17
%
Total MKTX U.S. Credit Portfolio Trading 6
1,441
1,328
748
93
9
Total U.S. Credit TRACE Portfolio Trading 6
7,349
6,608
5,744
28
11
Dealer-Initiated Channel
Total Dealer Initiated (DRFQ & Mid-X)
$
1,916
$
2,140
$
1,232
56
%
(10
)%
Other
Open Trading
$
5,739
$
5,485
$
3,973
44
%
5
%
AxessIQ
181
175
123
47
3
U.S. Trading Days 4
21
21
22
U.K. Trading Days 4
20
21
21
Expand
Table 1D: Variable Transaction Fees Per Million (FPM) 1
Month % Change
Apr-25 Mar-25 Apr-24 YoY MoM
AVG. VARIABLE TRANS. FEE PER MILLION (FPM)
Total Credit
$
139
$
136
$
150
(7
)%
2
%
Total Rates
4.23
4.61
4.40
(4
)
(8
)
Expand
1 The FPM for total credit and total rates for April 2025 are preliminary and may be revised in subsequent updates and public filings. The Company undertakes no obligation to update any fee information in future press releases.
2 Open Trading share of total credit trading volume is derived by taking total Open Trading volume across all credit products where Open Trading is offered and dividing by total credit trading volume across all credit products where Open Trading is offered.
3 'Other Credit Products' includes municipal bonds, leveraged loans, convertible bonds and structured products.
4 The number of U.S. trading days is based on the SIFMA holiday recommendation calendar and the number of U.K. trading days is based primarily on the U.K. Bank holiday schedule.
5 'SD PT' is defined as single-dealer portfolio trades. The Company is currently highlighting the impact of single-dealer portfolio trading volume on U.S. high-grade and U.S. high-yield trading volume and estimated market share, but will continue to exclude single-dealer portfolio trading activity from each product's aggregated trading volume and estimated market share and the total credit FPM calculation.
6 Due to variances in how portfolio trading market participants utilized the portfolio trading TRACE 'flag,' the Company previously used its own internal methodology for calculating portfolio trading as an estimated percentage of TRACE volume and the Company's estimated market share. Starting in June 2024, the Company utilized the portfolio trading TRACE flag in its reported portfolio trading TRACE volume and the Company's portfolio trading estimated market share.
Expand
General Notes Regarding the Data Presented
Reported MarketAxess volume in all product categories includes only fully electronic trading volume. MarketAxess trading volumes and the Financial Industry Regulatory Authority ('FINRA') Trade Reporting and Compliance Engine ('TRACE') reported volumes are available on the Company's website at investor.marketaxess.com/volume.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, including statements about the outlook and prospects for the Company, market conditions and industry growth, as well as statements about the Company's future financial and operating performance. These and other statements that relate to future results and events are based on MarketAxess' current expectations. The Company's actual results in future periods may differ materially from those currently expected or desired because of a number of risks and uncertainties, including: global economic, political and market factors; the level of trading volume transacted on the MarketAxess platform; the rapidly evolving nature of the electronic financial services industry; the level and intensity of competition in the fixed-income electronic trading industry and the pricing pressures that may result; the variability of our growth rate; our ability to introduce new fee plans and our clients' response; our ability to attract clients or adapt our technology and marketing strategy to new markets; risks related to our growing international operations; our dependence on our broker-dealer clients; the loss of any of our significant institutional investor clients; our exposure to risks resulting from non-performance by counterparties to transactions executed between our clients in which we act as an intermediary in matched principal trades; risks related to self-clearing; risks related to sanctions levied against states or individuals that could expose us to operational or regulatory risks; the effect of rapid market or technological changes on us and the users of our technology; issues related to the development and use of artificial intelligence; our dependence on third-party suppliers for key products and services; our ability to successfully maintain the integrity of our trading platform and our response to system failures, capacity constraints and business interruptions; the occurrence of design defects, errors, failures or delays with our platforms, products or services; our vulnerability to malicious cyber-attacks and attempted cybersecurity breaches; our actual or perceived failure to comply with privacy and data protection laws; our ability to protect our intellectual property rights or technology and defend against intellectual property infringement or other claims; our use of open-source software; our ability to enter into strategic alliances and to acquire other businesses and successfully integrate them with our business; our dependence on our management team and our ability to attract and retain talent; limitations on our flexibility because we operate in a highly regulated industry; the increasing government regulation of us and our clients; risks related to the divergence of U.K. and European Union legal and regulatory requirements following the U.K.'s exit from the European Union; our exposure to costs and penalties related to our extensive regulation; our risks of litigation and securities laws liability; our tax filing positions; the effects of climate change or other sustainability risks that could affect our operations or reputation; our future capital needs and our ability to obtain capital when needed; limitations on our operating flexibility contained in our credit agreement; our exposure to financial institutions by holding cash in excess of federally insured limits; and other factors. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these and other factors affecting MarketAxess' business and prospects is contained in MarketAxess' periodic filings with the Securities and Exchange Commission and can be accessed at www.marketaxess.com.
About MarketAxess
MarketAxess (Nasdaq: MKTX) operates a leading electronic trading platform that delivers greater trading efficiency, a diversified pool of liquidity and significant cost savings to institutional investors and broker-dealers across the global fixed-income markets. Approximately 2,100 firms leverage MarketAxess' patented technology to efficiently trade fixed-income securities. Our automated and algorithmic trading solutions, combined with our integrated and actionable data offerings, help our clients make faster, better-informed decisions on when and how to trade on our platform. MarketAxess' award-winning Open Trading® marketplace is widely regarded as the preferred all-to-all trading solution in the global credit markets. Founded in 2000, MarketAxess connects a robust network of market participants through an advanced full trading lifecycle solution that includes automated trading solutions, intelligent data and index products and a range of post-trade services. Learn more at www.marketaxess.com and on X @MarketAxess.
Table 2: Trading Volume Detail
Credit
High-grade
$
180,504
$
8,595
$
144,951
$
6,589
25
%
30
%
High-yield
41,319
1,968
31,416
1,428
32
38
Emerging markets
89,728
4,273
74,154
3,371
21
27
Eurobonds
55,703
2,785
42,564
2,027
31
37
Other credit
15,516
739
9,932
451
56
64
Total credit trading 1
382,770
18,360
303,017
13,866
26
32
Rates
U.S. government bonds 2
796,645
37,935
430,424
19,565
85
94
Agency and other government bonds 1
22,936
1,141
15,212
718
51
59
Total rates trading
819,581
39,076
445,636
20,283
84
93
Total trading
$
1,202,351
$
57,436
$
748,653
$
34,149
61
68
Number of U.S. Trading Days 3
21
22
Number of U.K. Trading Days 4
20
21
Year-to-Date Ended April 30,
In millions (unaudited)
2025
2024
% Change
Volume
ADV
Volume
ADV
Volume
ADV
Credit
High-grade
$
641,812
$
7,827
$
600,949
$
7,240
7
%
8
%
High-yield
131,316
1,601
116,795
1,407
12
14
Emerging markets
330,013
4,025
295,581
3,561
12
13
Eurobonds
203,620
2,453
171,413
2,041
19
20
Other credit
51,998
634
36,267
436
43
45
Total credit trading 1
1,358,759
16,540
1,221,005
14,685
11
13
Rates
U.S. government bonds 2
2,378,726
29,009
1,476,220
17,786
61
63
Agency and other government bonds 1
88,761
1,070
46,838
559
90
91
Total rates trading
2,467,487
30,079
1,523,058
18,345
62
64
Total trading
$
3,826,246
$
46,619
$
2,744,063
$
33,030
39
41
Number of U.S. Trading Days 3
82
83
Number of U.K. Trading Days 4
83
84
1 Consistent with FINRA TRACE reporting standards, both sides of trades are included in the Company's reported volumes when the Company executes trades on a matched principal basis between two counterparties.
2 Consistent with industry standards, U.S. government bond trades are single-counted.
3 The number of U.S. trading days is based on the SIFMA holiday recommendation calendar.
4 The number of U.K. trading days is based primarily on the U.K. Bank holiday schedule.
Expand

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
2 hours ago
- Yahoo
Down 21%, Should You Buy the Dip on Apple Stock? The Answer Might Surprise You.
It's the combination of products and services that has made Apple one of the best businesses on Earth. Ongoing uncertainty surrounding the tariff situation adds to investor concerns. At the current valuation, Apple stock provides zero margin of safety. 10 stocks we like better than Apple › Apple (NASDAQ: AAPL) shares are down 18% in 2025 (as of June 6). This makes Apple the worst-performing "Magnificent Seven" constituent this year, besides Tesla. Investors are probably concerned about tariff uncertainty and the company's slow progress with artificial intelligence (AI). The stock is currently 21% below its peak. So, it has some work to do to get back to its former glory. Legendary investor Warren Buffett and his conglomerate, Berkshire Hathaway, have sold a sizable chunk of their shares in the past several quarters. However, should you go against the Oracle of Omaha's moves and buy the dip on Apple stock? I think the answer might surprise you. I mention Buffett because many individual investors like to follow his buy and sell decisions. Clearly, when Berkshire first bought Apple in early 2016, they must've thought the tech giant was a high-quality enterprise. It's not hard to see why. Apple's brand is arguably the most recognizable in the world. This position wasn't created overnight. It took years and years of introducing truly exceptional products and services, that were well designed and incredibly easy to use, on a global scale. Apple is an icon, to say the least. That brand has helped drive Apple's pricing power. And this supports the company's unrivaled financial position. Apple remains an unbelievably profitable business. It brought in $24.8 billion in net income in the latest fiscal quarter (Q2 2025 ended March 29). Apple's products and services are impressive on their own. However, it's the combination of both of these aspects that creates the powerful ecosystem. Consumers are essentially locked in, which creates high barriers for them to switch to competing products. This favorable setup places Apple in an enviable position from a competitive perspective. Despite Apple's market cap of nearly $3.1 trillion, which might make some investors believe it's immune to external challenges, this business is dealing with some notable issues recently. There are three that immediately come to mind. The first problem is that Apple's growth engine seems to be decaying. Net sales were up less than 7% between fiscal 2021 and fiscal 2024. And they're up just over 4% through the first six months of fiscal 2025. According to management, there are likely over 2.4 billion active Apple devices across the globe. That number continues to rise with every passing quarter, but you get an idea of how ubiquitous these products are. Plus, the maturity of the iPhone, now almost two decades into its lifecycle, might lead to limited opportunities to further penetrate markets. Critics can also call out Apple's slow entrance into the AI race. For example, we won't see an AI update to Siri until next year, a launch that was delayed. At the same time, it seems like other companies are moving rapidly to win the AI race. Lastly, Apple has been and could continue to be drastically impacted by the tariff situation. China, which has gotten the most attention from President Donald Trump during the ongoing trade tensions, has been a manufacturing powerhouse for Apple. The business is being forced to shift its supply chain around to minimize the impact. Apple CEO Tim Cook said that the situation makes it challenging to forecast near-term results. Even though this stock trades 21% off its peak, investors aren't really getting a bargain deal here. The price-to-earnings ratio is 32 right now. That's not cheap for a company whose earnings per share are only expected to grow at a compound annual rate of 8.8% between fiscal 2024 and fiscal 2027. In my view, there's zero margin of safety. If you're an investor who wants to generate market-beating returns over the next five years, I don't think you should buy Apple today. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, and Tesla. The Motley Fool has a disclosure policy. Down 21%, Should You Buy the Dip on Apple Stock? The Answer Might Surprise You. was originally published by The Motley Fool